NEW YORK (GenomeWeb) – Bio-Techne today announced a deal to buy protein analysis technology firm ProteinSimple for $300 million in cash.
ProteinSimple has appointed Joe Keegan and Chris van Ingen to its board of directors.
Keegan was previously the CEO of ForteBio and Molecular Devices.
Quanterix this week launched a commercial, research-use-only version of its Single Molecule Array, Simoa, platform.
ProteinSimple said this week that it has hired Terry Salyer as vice president of sales.
By Adam Bonislawski
A team led by Stanford University researchers has developed a method for predicting response to cancer therapies based on cellular signaling protein dynamics and changes in tumor size.
By a GenomeWeb staff reporter
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.